Dianthus Therapeutics, Inc. (DNTH)
(Real Time Quote from BATS)
$21.44 USD
-0.72 (-3.25%)
Updated May 30, 2024 02:40 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Dianthus Therapeutics, Inc. (DNTH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$42.67 | $51.00 | $38.00 | 92.55% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Dianthus Therapeutics, Inc. comes to $42.67. The forecasts range from a low of $38.00 to a high of $51.00. The average price target represents an increase of 92.55% from the last closing price of $22.16.
Analyst Price Targets (6 )
Broker Rating
Dianthus Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 83.33%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.17 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/16/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Not Available | Strong Buy |
4/18/2024 | Raymond James | Steven Seedhouse | Moderate Buy | Moderate Buy |
3/22/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
1/31/2024 | Evercore Partners | Gavin Clark-Gartner | Not Available | Strong Buy |
10/30/2023 | Guggenheim Securities | Yatin Suneja | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 7 |
Average Target Price | $42.67 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 90 of 252 |
Current Quarter EPS Est: | -0.49 |